Ad.net is a privately held digital performance advertising solutions provider based in Los Angeles, United States. Founded in 2001, the company offers real-time bidding (RTB) and programmatic advertising services. With a team of approximately 90 employees, Ad.net focuses on delivering effective and efficient advertising campaigns for its clients.
Ad.net received approval from the Medicines and Healthcare Products Regulatory Agency for the use of Lecanemab in the UK. The Therapeutic Goods Administration is currently evaluating the drug for use in Australia. Lecanemab has also been approved in the USA, Japan, China, South Korea, and Israel. Meanwhile, Ad.net is facing controversy due to revelations about CEO Jon Waterman's past. Additionally, the company highlights the significance of digital advertising in today's business landscape, particularly search advertising for its targeting capabilities and potential return on investment.
Subscribe for full access to Ad.net's products in full detail 
